Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis

O

Opsidio

Status and phase

Active, not recruiting
Phase 2

Conditions

Atopic Dermatitis

Treatments

Biological: OpSCF
Biological: Placebo
Biological: OpSCF (Open Label Extension)

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06101823
OpSCF-201

Details and patient eligibility

About

The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo. OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.

Enrollment

48 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject has clinically confirmed diagnosis of active AD
  • Subject has at least a 6-month history of AD
  • Subject is willing to use effective birth control

Exclusion criteria

  • Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
  • Subject has any clinically significant medical condition that would put the subject at undue risk or interfere with interpretation of study results.
  • Subject has used dupilumab within 26 weeks prior to Day 1
  • Subject has used tralokinumab within 12 weeks prior to Day 1

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

48 participants in 3 patient groups, including a placebo group

OpSCF
Active Comparator group
Description:
OpSCF, 600 mg, subcutaneously, every two weeks x 14 weeks
Treatment:
Biological: OpSCF
Placebo
Placebo Comparator group
Description:
Matched placebo, subcutaneously, every two weeks x 14 weeks
Treatment:
Biological: Placebo
Open Label Extension
Active Comparator group
Description:
Subjects may choose to continue in an Open Label Extension (OLE) phase if they complete the randomized phase. All subjects regardless of treatment assignment in the randomized phase will receive OpSCF, 600 mg every 4 weeks for up to 36 weeks.
Treatment:
Biological: OpSCF (Open Label Extension)
Biological: OpSCF

Trial contacts and locations

22

Loading...

Central trial contact

Study Director

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems